BioNTech

Management focus is on a strong balance sheet

20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."

PDF page sample
Pages
59
Language
English
Published on
20/11/23
Download
You may also be interested by these reports :
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...
04/09/26
We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) ...
27/08/26
While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last ...
26/08/26
We upgrade Novonesis to ADD from Reduce. The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO